HC Wainwright Affirms Buy Rating on Lineage Cell Therapeutics Amid Type 1 Diabetes Push

HC Wainwright reiterated a 'Buy' rating on Lineage Cell Therapeutics (LCTX) with a $9 price target, citing its strong performance and potential in treating Type 1 diabetes through its new islet cell transplant program. The program leverages the company's experience in cell manipulation and could lead to functional cures based on early data.

September 12, 2025 - Financial markets have been abuzz with positive developments surrounding Lineage Cell Therapeutics, Inc. (NYSE: LCTX), as analysts have reiterated their bullish views on the biotech company following a series of strong earnings reports and strategic partnerships. The company, which focuses on developing allogeneic cell therapies for neurological and ophthalmic disorders, has seen its stock price gain traction.

Analyst Ratings and Price Targets

Baird Financial has reiterated its Outperform rating on Lineage Cell Therapeutics, maintaining a $5.00 price target Baird reiterates Outperform rating on Lineage Cell stock ...^[1]. The research firm highlighted Roche's (OTC: RHHBY) R&D Day, where multiple slides were dedicated to the OpRegen program, signaling continued commitment to the collaboration. Roche's SVP of ophthalmology referred to OpRegen as a "personal favorite," further bolstering confidence in the program's potential.

In a separate move, H.C. Wainwright & Co. reaffirmed its Buy rating on Lineage Cell Therapeutics, setting a $9.00 price target Lineage Cell Therapeutics, Inc. (LCTX) Shows Vision Gains in Phase 1/2a OpRegen Trial^[2]. The firm cited the company's strong performance and potential in treating Type 1 diabetes through its new islet cell transplant program. This initiative leverages Lineage's expertise in cell manipulation and could lead to functional cures based on early data.

Financial Performance and Strategic Partnerships

Lineage Cell Therapeutics reported its second quarter 2025 earnings, showcasing a significant revenue increase to $2.8 million, which exceeded analyst expectations Baird reiterates Outperform rating on Lineage Cell stock after Roche R&D Day^[3]. Despite the revenue boost, the company experienced a net loss of $0.13 per share, which was larger than anticipated. This indicates that the company is continuing to invest heavily in research and development.

Moreover, Lineage Cell Therapeutics entered into a research collaboration with William Demant Invest A/S to advance the development of ReSonance (ANP1), a cell therapy aimed at treating hearing loss Baird reiterates Outperform rating on Lineage Cell stock after Roche R&D Day^[3]. William Demant Invest will provide up to $12 million over three years to support preclinical development activities, including cell manufacturing, proof-of-concept studies, and regulatory strategy. This collaboration underscores the company's ongoing efforts to expand its therapeutic offerings and strategic partnerships.

Clinical Milestones and Future Prospects

In addition to its financial and partnership developments, Lineage Cell Therapeutics has made significant strides in its clinical pipeline. The company reported positive 36-month Phase 1/2a results for RG6501 (OpRegen), a retinal pigment epithelial therapy for geographic atrophy, a form of age-related macular degeneration Lineage Cell Therapeutics, Inc. (LCTX) Shows Vision Gains in Phase 1/2a OpRegen Trial^[2]. Patients showed sustained vision improvements of +6.2 ETDRS letters, suggesting potential disease stabilization from a single administration. Furthermore, Lineage treated its first chronic spinal cord injury patient in a new OPC1 trial, marking a milestone in expanding clinical applications beyond ophthalmology.

Conclusion

The positive analyst ratings and strong financial performance of Lineage Cell Therapeutics underscore the company's potential in the biotech sector. With a robust pipeline of cell therapies and strategic partnerships, the company is well-positioned to make significant strides in treating various disorders. Investors and financial professionals should closely monitor the company's progress as it continues to innovate and expand its therapeutic offerings.